thiotepa has been researched along with Cardiac Rupture, Traumatic in 1 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreri, AJ | 1 |
| Cwynarski, K | 1 |
| Pulczynski, E | 1 |
| Ponzoni, M | 1 |
| Deckert, M | 1 |
| Politi, LS | 1 |
| Torri, V | 1 |
| Fox, CP | 1 |
| Rosée, PL | 1 |
| Schorb, E | 1 |
| Ambrosetti, A | 1 |
| Roth, A | 1 |
| Hemmaway, C | 1 |
| Ferrari, A | 1 |
| Linton, KM | 1 |
| Rudà, R | 1 |
| Binder, M | 1 |
| Pukrop, T | 1 |
| Balzarotti, M | 1 |
| Fabbri, A | 1 |
| Johnson, P | 1 |
| Gørløv, JS | 1 |
| Hess, G | 1 |
| Panse, J | 1 |
| Pisani, F | 1 |
| Tucci, A | 1 |
| Stilgenbauer, S | 1 |
| Hertenstein, B | 1 |
| Keller, U | 1 |
| Krause, SW | 1 |
| Levis, A | 1 |
| Schmoll, HJ | 1 |
| Cavalli, F | 1 |
| Finke, J | 1 |
| Reni, M | 1 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra[NCT01011920] | Phase 2 | 126 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thiotepa and Cardiac Rupture, Traumatic
| Article | Year |
|---|---|
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System | 2016 |